<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-1720972-B1" country="EP" doc-number="1720972" kind="B1" date="20140108" family-id="34961830" file-reference-id="318233" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146589065" ucid="EP-1720972-B1"><document-id><country>EP</country><doc-number>1720972</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-05715787-A" is-representative="NO"><document-id mxw-id="PAPP154851257" load-source="docdb" format="epo"><country>EP</country><doc-number>05715787</doc-number><kind>A</kind><date>20050304</date><lang>EN</lang></document-id><document-id mxw-id="PAPP175857587" load-source="docdb" format="original"><country>EP</country><doc-number>05715787.7</doc-number><date>20050304</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140551039" ucid="EP-04075702-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>04075702</doc-number><kind>A</kind><date>20040305</date></document-id></priority-claim><priority-claim mxw-id="PPC140552226" ucid="EP-04075703-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>04075703</doc-number><kind>A</kind><date>20040305</date></document-id></priority-claim><priority-claim mxw-id="PPC140556436" ucid="EP-04077656-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>04077656</doc-number><kind>A</kind><date>20040927</date></document-id></priority-claim><priority-claim mxw-id="PPC140555845" ucid="EP-04077657-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>04077657</doc-number><kind>A</kind><date>20040927</date></document-id></priority-claim><priority-claim mxw-id="PPC140550571" ucid="EP-05715787-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>05715787</doc-number><kind>A</kind><date>20050304</date></document-id></priority-claim><priority-claim mxw-id="PPC140556672" ucid="EP-2005002374-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>2005002374</doc-number><kind>W</kind><date>20050304</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130606</date></intention-to-grant-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989327504" load-source="docdb">C12M   3/06        20060101AFI20051019BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989633611" load-source="docdb">C12N   5/00        20060101A I20070721RMEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1840015589" load-source="docdb" scheme="CPC">C12M  41/44        20130101 LA20170307BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2019259896" load-source="docdb" scheme="CPC">C07K  16/00        20130101 LI20150929BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2019266750" load-source="docdb" scheme="CPC">C07K2317/14        20130101 LA20150929BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2048045534" load-source="docdb" scheme="CPC">C12M  29/10        20130101 LI20150612BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2048048202" load-source="docdb" scheme="CPC">C12N   5/00        20130101 LI20150612BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2048050956" load-source="docdb" scheme="CPC">C12M  25/10        20130101 LI20150612BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2048051117" load-source="docdb" scheme="CPC">C12N2521/00        20130101 LA20150612BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989625036" load-source="docdb" scheme="CPC">C12P  21/00        20130101 LI20131003BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989651366" load-source="docdb" scheme="CPC">C12P  19/34        20130101 LI20131003BHEP        </classification-cpc><classification-cpc mxw-id="PCL2065202256" load-source="docdb" scheme="CPC">C12N   5/0602      20130101 LI20140328BHEP        </classification-cpc><classification-cpc mxw-id="PCL2065202257" load-source="docdb" scheme="CPC">C12N   5/0621      20130101 FI20140320BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132371828" lang="DE" load-source="patent-office">VERFAHREN ZUR ZELLKULTIVIERUNG MIT DAUERPERFUSION UND WECHSELNDEM TANGENTIALSTROM</invention-title><invention-title mxw-id="PT132371829" lang="EN" load-source="patent-office">PROCESS FOR CELL CULTURING BY CONTINUOUS PERFUSION AND ALTERNATING TANGENTIAL FLOW</invention-title><invention-title mxw-id="PT132371830" lang="FR" load-source="patent-office">CULTURE DE CELLULES EN PERFUSION CONTINUE ET FLUX ALTERNATIF TANGENTIEL</invention-title></technical-data><related-documents><relation type="division-into"><child-doc ucid="EP-10183651.8"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>10183651.8</doc-number><date>20100930</date></document-id></child-doc><parent-doc ucid="EP-05715787-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>05715787</doc-number><kind>A</kind><date>20050304</date></document-id><parent-grant-document ucid="EP-1720972-B1"><document-id><country>EP</country><doc-number>1720972</doc-number><kind>B1</kind><date>20140108</date></document-id></parent-grant-document></parent-doc></relation><relation type="division-into"><child-doc ucid="EP-12186351.8"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>12186351.8</doc-number><date>20120927</date></document-id></child-doc><parent-doc ucid="EP-05715787-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>05715787</doc-number><kind>A</kind><date>20050304</date></document-id><parent-grant-document ucid="EP-1720972-B1"><document-id><country>EP</country><doc-number>1720972</doc-number><kind>B1</kind><date>20140108</date></document-id></parent-grant-document></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR919512102" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>DSM IP ASSETS BV</last-name><address><country>NL</country></address></addressbook></applicant><applicant mxw-id="PPAR919524207" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>DSM IP ASSETS B.V.</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919529662" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>CROWLEY JOHN</last-name><address><country>IE</country></address></addressbook></inventor><inventor mxw-id="PPAR919524245" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>CROWLEY, JOHN</last-name></addressbook></inventor><inventor mxw-id="PPAR919026179" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>CROWLEY, John, Wyeth Medica Ireland</last-name><address><street>Grange Castle Business Park, Clondalkin</street><city>22 DUBLIN</city><country>IE</country></address></addressbook></inventor><inventor mxw-id="PPAR919546251" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>WUEBBEN MAIKE</last-name><address><country>NL</country></address></addressbook></inventor><inventor mxw-id="PPAR919527328" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>WUEBBEN, MAIKE</last-name></addressbook></inventor><inventor mxw-id="PPAR919026176" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>WÜBBEN, Maike</last-name><address><street>Steenhouwerskade 17</street><city>NL-GRONINGEN 9718 DB</city><country>NL</country></address></addressbook></inventor><inventor mxw-id="PPAR919505876" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>COCO MARTIN JOSE MANUEL</last-name><address><country>NL</country></address></addressbook></inventor><inventor mxw-id="PPAR919517827" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>COCO MARTIN, JOSE MANUEL</last-name></addressbook></inventor><inventor mxw-id="PPAR919026175" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>COCO MARTIN, JOSE MANUEL</last-name><address><street>Jachtlaan 20</street><city>NL-9301 KP Roden</city><country>NL</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919026177" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>DSM IP Assets B.V.</last-name><iid>100112615</iid><address><street>Het Overloon 1</street><city>6411 TE Heerlen</city><country>NL</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919026178" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Heijman, Renske Harriët</last-name><suffix>et al</suffix><iid>100768122</iid><address><street>DSM Intellectual Property P.O. Box 9</street><city>6160 MA Geleen</city><country>NL</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="EP-2005002374-W"><document-id><country>EP</country><doc-number>2005002374</doc-number><kind>W</kind><date>20050304</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2005095578-A1"><document-id><country>WO</country><doc-number>2005095578</doc-number><kind>A1</kind><date>20051013</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549875263" load-source="docdb">AT</country><country mxw-id="DS549790914" load-source="docdb">BE</country><country mxw-id="DS549807050" load-source="docdb">BG</country><country mxw-id="DS549926282" load-source="docdb">CH</country><country mxw-id="DS549793187" load-source="docdb">CY</country><country mxw-id="DS549875264" load-source="docdb">CZ</country><country mxw-id="DS549790915" load-source="docdb">DE</country><country mxw-id="DS549793188" load-source="docdb">DK</country><country mxw-id="DS549793193" load-source="docdb">EE</country><country mxw-id="DS549899260" load-source="docdb">ES</country><country mxw-id="DS549807051" load-source="docdb">FI</country><country mxw-id="DS549926283" load-source="docdb">FR</country><country mxw-id="DS549790916" load-source="docdb">GB</country><country mxw-id="DS549793194" load-source="docdb">GR</country><country mxw-id="DS549875265" load-source="docdb">HU</country><country mxw-id="DS549890435" load-source="docdb">IE</country><country mxw-id="DS549793195" load-source="docdb">IS</country><country mxw-id="DS549926284" load-source="docdb">IT</country><country mxw-id="DS549793196" load-source="docdb">LI</country><country mxw-id="DS549807052" load-source="docdb">LT</country><country mxw-id="DS549883958" load-source="docdb">LU</country><country mxw-id="DS549807053" load-source="docdb">MC</country><country mxw-id="DS549890436" load-source="docdb">NL</country><country mxw-id="DS549890441" load-source="docdb">PL</country><country mxw-id="DS549807054" load-source="docdb">PT</country><country mxw-id="DS549875270" load-source="docdb">RO</country><country mxw-id="DS549890442" load-source="docdb">SE</country><country mxw-id="DS549926285" load-source="docdb">SI</country><country mxw-id="DS549899265" load-source="docdb">SK</country><country mxw-id="DS549883959" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63961480" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><p id="p0001" num="0001">The present invention relates to the reduction of aggregation of cells in a cell culture.</p><p id="p0002" num="0002"><nplcit id="ncit0001" npl-type="s"><text>Kyung et al. (1994) (Cytotechnology 14, 183-190</text></nplcit>) relates to the high cell density culturing of mammalian cells, and in particular of a recombinant human kidney epithelial cell line (indicated as the 293 cell line). These cells have a tendency to aggregate, with concomitant death of the cells at the center of these aggregates. Kyung et al show that this tendency to aggregate can be influenced by lowering the concentration of Ca<sup>2+</sup> in the cell culture medium. However, even at a very low concentration of Ca<sup>2+</sup> (100µM) large aggregates were formed during culturing over a prolonged period.</p><p id="p0003" num="0003"><patcit id="pcit0001" dnum="WO9305145A"><text>WO93/05145</text></patcit> describes the culturing of Chinese Hamster Ovary (CHO) cell and the prevention of formation aggregates in such CHO cell cultures. Apart from the possibility of reducing the Ca<sup>2+</sup> concentration (which is undesired because calcium ions are required for cell growth), <patcit id="pcit0002" dnum="WO9305145A"><text>WO93/05145</text></patcit> discloses that controlling the molar ratio of total inorganic ions and total amino acids in the nutrient medium can result in reduction of the aggregation of the CHO cells.</p><p id="p0004" num="0004">The present invention discloses the use of a perfusion cell culturing process wherein a cell culture comprising cell culture medium and a suspension of cells is circulated over a filter module comprising hollow fibers wherein the flow within the filter module is an alternating tangential flow, for the reduction of the degree of aggregation of the cells in the cell culture wherein these cells have the tendency to easily or inherently form aggregates during culturing according to claim 1.</p><p id="p0005" num="0005">It has surprisingly been found that by perfusion culturing of animal, in particular mammalian, cells or yeast cells according to the invention, extremely high viable cell densities can be obtained, whereas the cell culture further displays an extremely high cell viability. Furthermore, it was found that the perfusion process of the invention leads to less cell aggregation in the culture, and even to a culture being a suspension of single cells without visible aggregates. This is a surprising finding because the use of<!-- EPO <DP n="2"> --> low shear conditions, such as in perfusion cell culturing, typically does not lead to disaggregation of cells. Cell aggregation during perfusion cell culturing is<!-- EPO <DP n="3"> --> disadvantageous, because process control is more difficult, due to, for example, the heterogeneity in metabolic profiles of cells within the cell aggregates. This is especially troublesome if cells form aggregates of 5 cells or more and when the aggregates comprise in total 5 % or more of the total amount of cells.</p><p id="p0006" num="0006">A perfusion process is described in <patcit id="pcit0003" dnum="US6544424B"><text>US 6,544,424</text></patcit>. Although this document mentions that this process may be used for perfusion culturing of animal cells, it does neither disclose nor suggest the extremely high cell densities found in the present invention. Furthermore, <patcit id="pcit0004" dnum="US6544424B1"><text>US 6,544,424 B1</text></patcit> discloses that the perfusion process could diminish the attachment and growth of an obstruction on the membrane surface of the hollow fibers, but it does neither disclose nor suggest that cells in the cell culture itself would aggregate less.</p><p id="p0007" num="0007">The same perfusion process is described in an article by Furey (<nplcit id="ncit0002" npl-type="s"><text>J. Furey, Continuous Cell Culture Using the ATF System, Genetic Engineering News, Volume 20, Number 10, May 15, 2000, pages 52-53</text></nplcit>). The hollow fiber system which is used during the perfusion culturing process described therein, was cited to be prone to clogging by accumulation of particulates and gelatin on the membrane surface, as well as that upon recirculation of the cell culture through the hollow fiber module the inlets of the hollow fiber lumens will clog. Application of an alternating tangential flow is reported to prevent such clogging and fouling, but this article neither discloses nor suggests that cells in the cell culture itself would aggregate less.</p><p id="p0008" num="0008"><nplcit id="ncit0003" npl-type="s"><text>Voisier et al. (Biotechnol. Bioeng. 82 (2003), 751-765</text></nplcit>) review various cell retention techniques in high-density perfusion culture of suspended mammalian cells. None of the reviewed cell retention systems is able to provide the extremely high viable cell densities combined with the extremely high cell viability, of the present invention. Furthermore, this article neither discloses nor suggests that cells in the cell culture itself would aggregate less upon application of an alternating tangential flow during the cell culturing.</p><p id="p0009" num="0009">Perfusion culturing of cells has its conventional meaning in the art, i.e. it means that during culturing cells are retained by a separation device in which there is an<!-- EPO <DP n="4"> --> outflow of liquid having a lower cell density than prior to separation and in which there is an inflow of the cell culture medium. In the process of the present invention, the separation device is a filter module comprising hollow fibers.</p><p id="p0010" num="0010">Perfusion culturing includes, but is not limited to continuous flow and semi-continuous flow, for example step-wise flow or staggered flow.</p><p id="p0011" num="0011">With the term "hollow fiber" is meant a tubular membrane. The internal diameter of the tube is preferably between 0.3 and 6.0 mm, more preferably between 0.5 and 3.0 mm, most preferably between 0.5 and 2.0 mm. Preferably, the mesh size in the membrane is chosen such that the size of the pores in the mesh is close to the diameter of the cells, ensuring a high retention of cells while cell debris can pass the filter. Preferably, the mesh size is between 3-30 µm.</p><p id="p0012" num="0012">Filter modules comprising hollow fibers are commercially available from for example General Electric (formerly Amersham).</p><p id="p0013" num="0013">With "alternating tangential flow within the filter module" is meant that there is one flow in the same direction as (i.e. tangential to) the membrane surfaces of the hollow fibers, which flow is going back and forth, and that there is another flow in a direction substantially perpendicular to said filter surface. Tangential flow can be achieved according to methods known to the person skilled in the art. For example, in <patcit id="pcit0005" dnum="US6544424B"><text>US 6,544,424</text></patcit> it is described that alternating tangential flow can be achieved using one pump to circulate the cell culture over a filter module comprising hollow fibers and another pump to remove the liquid having a lower cell density than prior to the filter separation.</p><p id="p0014" num="0014">In the process of the invention, any type of cell culture medium suitable for the culturing of cells can in principle be used. Guidelines for choosing a cell culture medium and cell culture conditions are well known in the art and are for instance provided in <nplcit id="ncit0004" npl-type="b"><text>Chapter 8 and 9 of Freshney, R. I. Culture of animal cells (a manual of basic techniques), 4th edition 2000, Wiley-Liss</text></nplcit> and in <nplcit id="ncit0005" npl-type="b"><text>Doyle, A., Griffiths, J. B., Newell, D. G. Cell &amp;Tissue culture: Laboratory Procedures 1993, John Wiley &amp; Sons</text></nplcit>.</p><p id="p0015" num="0015">Generally, a cell culture medium for mammalian cells comprises salts, amino acids, vitamins, lipids, detergents, buffers, growth factors, hormones, cytokines, trace elements and carbohydrates. Examples of salts include magnesium salts, for example MgCl<sub>2</sub>.6H<sub>2</sub>O, MgSO<sub>4</sub> and MgSO<sub>4</sub>.7H<sub>2</sub>O iron salts, for example FeSO<sub>4</sub>.7H<sub>2</sub>O, potassium salts, for example KH<sub>2</sub>PO<sub>4</sub>, KCl; sodium salts, for example NaH<sub>2</sub>PO<sub>4</sub>, Na<sub>2</sub>HPO<sub>4</sub> and calcium salts, for example CaCl<sub>2</sub>.2H<sub>2</sub>O. Examples of amino acids are all 20 known<!-- EPO <DP n="5"> --> proteinogenic amino acids, for example histidine, glutamine, threonine, serine, methionine. Examples of vitamins include: ascorbate, biotin, choline.Cl, myo-inositol,<!-- EPO <DP n="6"> --> D-panthothenate, riboflavin. Examples of lipids include: fatty acids, for example linoleic acid and oleic acid; soy peptone and ethanol amine. Examples of detergents include Tween 80 and Pluronic F68. An example of a buffer is HEPES. Examples of growth factors/hormones/cytokines include IGF, hydrocortisone and (recombinant) insulin. Examples of trace elements are known to the person skilled in the art and include Zn, Mg and Se. Examples of carbohydrates include glucose, fructose, galactose and pyruvate.</p><p id="p0016" num="0016">The pH, temperature, dissolved oxygen concentration and osmolarity of the cell culture medium are in principle not critical and depend on the type of cell chosen. Preferably, the pH, temperature, dissolved oxygen concentration and osmolarity are chosen such that it is optimal for the growth and productivity of the cells. The person skilled in the art knows how to find the optimal pH, temperature, dissolved oxygen concentration and osmolarity for the perfusion culturing. Usually, the optimal pH is between 6.6 and 7.6, the optimal temperature between 30 and 39°C, the optimal osmolarity between 260 and 400mOsm/kg.</p><p id="p0017" num="0017">Cells that are advantageously subjected to the process of the invention may be any cell type benefiting from this process, i.e. culturing to an extremely high viable cell density and an extremely high cell viability.</p><p id="p0018" num="0018">According to the process of the invention, an extremely high viable cell density is a density of at least 80 x 10<sup>6</sup> cells per mL, preferably at least 100 x 10<sup>6</sup> cells per mL, more preferably at least 110 x 10<sup>6</sup> cells per mL, more preferably at least 120 x 10<sup>6</sup> cells per mL, more preferably at least 130 x 10<sup>6</sup> cells per mL, most preferably at least 140 x 10<sup>6</sup> cells per mL. Typically, a suitable upper limit in the cell density may lie around 500 x 10<sup>6</sup> cells per mL.</p><p id="p0019" num="0019">Surprisingly, the extremely high cell density of the process of the invention is accompanied by an extremely high cell viability. An extremely high cell viability is a viability of at least 90%, preferably at least 95%, more preferably at least 97%, most preferably at least 99%.</p><p id="p0020" num="0020">It is to be understood that the very high viable cell density and very high cell viability are reached after a certain period of perfusion culturing, generally when the cells have reached a steady state, for mammalian cells typically 12 to 25 days after the initiation of perfusion culturing.</p><p id="p0021" num="0021">The process of the invention is suitable for culturing animal cells or yeast cells, especially for culturing mammalian cells.<!-- EPO <DP n="7"> --></p><p id="p0022" num="0022">The process of the invention is suitable for culturing cells that easily or inherently form aggregates during culturing, especially during perfusion<!-- EPO <DP n="8"> --> culturing (so-called aggregating cells). Surprisingly, the process of the invention not only diminishes aggregate disposal on the filter membrane, but also diminishes aggregation of cells during the perfusion culture process, even aggregation of cells with an inherent tendency to form aggregates. The culturing of aggregating cells according to the invention results in a culture wherein aggregates of at least 5 cells comprise at the most 5 % of the total amount of cells, preferably at the most 4 %, more preferably at the most 3 %, even more preferably at the most 2 % of the total amount of cells. Especially preferably, the culturing of aggregating cells according to the invention results in a culture that is a real single cell suspension.</p><p id="p0023" num="0023">Aggregating cells are cells that form aggregates of at least 5 cells, the aggregates comprising in total at least 5 % of the total amount of cells. Preferably, the aggregates consist of at least 6, more preferably at least 7, even more preferably at least 8, even more preferably at least 9, even more preferably at least 10 cells. Preferably, the aggregates comprise in total at least 7%, more preferably at least 10 %, most preferably at least 15% of the total amount of cells.</p><p id="p0024" num="0024">Examples of mammalian cells include: CHO (Chinese Hamster Ovary) cells, hybridomas, BHK (Baby Hamster Kidney) cells, myeloma cells, human cells, for example HEK-293 cells, human lymphoblastoid cells, PER.C6® cells, mouse cells, for example NS0 cells. Examples of yeast cells include <i>Saccharomyces cerevisiae, Phaffia rhodozyma, Kluyveromyces lactis,</i> or yeast cells from the genus <i>Pichia .</i></p><p id="p0025" num="0025">Preferably, mammalian cells are used, more preferably CHO, NSO, PER.C6® cells. Also preferably, cells known for their aggregating behaviour during culturing (aggregating cells) are used. Most preferably, PER.C6® cells are used.</p><p id="p0026" num="0026">Cell aggregation may for example be determined under a microscope.</p><p id="p0027" num="0027">The rate of addition of cell culture medium to the culture (the inflow rate or perfusion rate) influences the viability and the density of the cells.</p><p id="p0028" num="0028">In one embodiment of the invention, the cell culture medium is added at a perfusion rate according to the following formula 1: <maths id="math0001" num="(1)"><math display="block"><mi>Perfusion rate</mi><mo>=</mo><mi>SPR</mi><mo>*</mo><mi>total cell culture volume</mi><mo>*</mo><mi>viable cell density</mi></math><img id="ib0001" file="imgb0001.tif" wi="137" he="7" img-content="math" img-format="tif"/></maths><br/>
wherein the perfusion rate is expressed in liters per day, wherein the SPR is the specific perfusion rate, i.e. the rate in which the cell culture medium is fed to the cell culture expressed as the volume of medium added per viable cell per time unit and wherein the viable cell density is the number of viable cells per unit of volume. The number of viable cells can be determined by the person skilled in the art, for example<!-- EPO <DP n="9"> --> via the trypan blue exclusion method.</p><p id="p0029" num="0029">The specific perfusion rate is preferably chosen between 0.01 and 0.3 nL/cell/day, more preferably between 0.01 and 0.2 nL/cell/day.</p><p id="p0030" num="0030">It may be of advantage to take into account additional parameters when adjusting the perfusion rate, for example the amount of glucose to be fed to the culture and/or the oxygen concentration. For example, for PER.C6® the glucose perfusion rate is preferably chosen between 3 and 20 mmoles/L, more preferably between 5 and 15 mmoles/L, as part of the medium perfusion rate.</p><p id="p0031" num="0031">A person skilled in the art knows how to determine the outflow rate. The outflow rate of the liquid is determined by the perfusion rate and is generally chosen at an equal value.</p><p id="p0032" num="0032">In one embodiment of the invention, the outflow liquid is substantially devoid of viable cells.</p><p id="p0033" num="0033">In another embodiment of the invention, biomass (i.e. cells in cell culture) is removed at least once from the cell culture and additional cell culture medium is added to the cell culture to compensate for the biomass removal. Biomass removal may lead to higher cell densities. Biomass may be removed continuously or step-wise.</p><p id="p0034" num="0034">In the step-wise approach, biomass is removed continuously for a defined time period. If a step-wise approach is used, biomass removal is preferably started just before or just after the cells have reached a steady state.</p><p id="p0035" num="0035">If a step-wise approach is used, a volume of biomass of preferably between 2 and 40 % of the working volume per day, more preferably between 5 and 30% of the working volume per day, even more preferably between 10 and 25% of the working volume per day is removed per biomass removal step.</p><p id="p0036" num="0036">With "working volume" is meant the total volume of the cell culture.</p><p id="p0037" num="0037">With "biomass removal step" is meant the time from the start to the stop of the biomass removal. If a continuous approach is used, the biomass is removed continuously until the end of the cell culturing. Preferably, the continuous removal of biomass is started just before or just after the cells have reached a steady state. Preferably, a volume of biomass is removed of between 2 and 40 % of the working volume per day, more preferably between 3 and 30% of the working volume per day, even more preferably between 4 and 15% of the working volume per day.</p><p id="p0038" num="0038">The addition of the additional cell culture medium is done to compensate for the biomass removal. The feed wherein additional cell culture medium is added to the cell culture may be merged into the perfusion feed, but may also be added in a separate feed. The person skilled in the art is aware how much additional cell culture medium is<!-- EPO <DP n="10"> --> needed to compensate for the biomass removal. Generally, the rate of addition of the additional cell culture medium to the cell culture will be the same as the biomass removal rate.</p><p id="p0039" num="0039">In yet another embodiment of the invention, a biological substance is produced by the cells. The biological substances that can suitably be produced in the perfusion culturing of the cell are in principle all biological substances that can be produced by animal, especially mammalian, and yeast cells, for example therapeutic and diagnostic proteins, such as monoclonal antibodies, growth factors or peptide hormones, enzymes, polynucleotides, such as viral vectors used in gene therapy, vaccines, etc.</p><p id="p0040" num="0040">In the perfusion culturing process of the invention, the outflow liquid will have a lower cell density but the same concentration of the biological substance than the liquid prior to separation.</p><p id="p0041" num="0041">Preferably, the process according to the invention is used for the production of a biopharmaceutical product, which is a biological substance with a medical application. Examples of biopharmaceutical products are as follows (with examples of brand names of the corresponding biopharmaceutical product between brackets): Tenecteplase (TN Kase™), (recombinant) antihemophilic factor (ReFacto™), lymphoblastoid Interferon α-n1 (Wellferon™), (recombinant) Coagulation factor (NovoSeven™), Etanercept, (Enbrel™), Trastuzumab (Herceptin™), Infliximab (Remicade™), Basiliximab (Simulect™), Daclizumab (Zenapaz™), (recombinant) Coagulation factor IX (Benefix™), erythropoietin alpha (Epogen®), G-CSF (Neupogen®Filgrastim), Interferon alpha-2b (Infergen®), recombinant insulin (Humulin®), Interferon beta 1a (Avonex®), Factor VIII (KoGENate®), Glucocerebrosidase (Cerezyme™), Interferon beta 1b (Betaseron®), TNF alpha receptor (Enbrel®), Follicle stimulating hormone (Gonal-F®), Mab abcixmab (Synagis@, ReoPro®), Mab ritiximab (Rituxan®), tissue plasminogen activator (Activase ®, Actilyase®), human growth hormone (Protropin®, Norditropin®, GenoTropin™). Examples of polynucleotides with a possible medical application are gene therapeutic plasmid DNAs. Some gene therapeutic DNAs are presently tested in clinical trials for their medical application. Examples of vaccines are live, oral, tetravalent Rotavirus vaccine (RotaShield™), rabies vaccine (RanAvert™), Hepatitis B vaccin (RECOMBIVAX HB®, Engerix®) and inactivated hepatitis A vaccine (VAQTA™).</p><p id="p0042" num="0042">The biological substance in the outflow may be further purified in so-called downstream processing. Downstream processing usually comprises several purification steps in varying combinations and order. Examples of purification steps in<!-- EPO <DP n="11"> --> the downstream processing are separation steps (e.g. by affinity chromatography and/or ion exchange chromatography), steps for the concentration of the biological substance (e.g. by ultrafiltration or diafiltration), steps to exchange buffers and/or steps to remove or inactivate viruses (e.g. by virus filtration, pH shift or solvent detergent treatment).</p><p id="p0043" num="0043">The invention will now be elucidated by way of the following examples, without however being limited thereto.</p><heading id="h0001"><b><u>Example 1: Process Optimisation of the Human Cell Line PER.C6</u><sup><u>®</u></sup><u>for the production of Biopharmaceuticals</u></b></heading><heading id="h0002"><u>Introduction</u></heading><p id="p0044" num="0044">A number of expression platforms now exist for the production of biopharmaceuticals. Most of the new products must choose a mammalian system due in main part to the glycosylation machinery which these cells contain and others lack. However to date the cell mass and resulting productivity of these cells is a factor of 10 -100 times less than a corresponding microbial system if these cells had the machinery to make such products.</p><p id="p0045" num="0045">A perfusion culture setup was developed for the PER.C6<sup>®</sup> cell line, a human cell line that possesses a number of features that makes it favourable for the production of biopharmaceuticals. A perfusion setup involves the separation of various components of the culture broth so that cells are retained, harvest is captured and medium refreshment occurs. The performance of a spin filter, an acoustic device and an Alternating Tangential Flow (ATF) unit within a continuous perfusion culture of the PER.C6<sup>®</sup> cell line was assessed.</p><heading id="h0003"><u>Materials &amp; Methods</u></heading><p id="p0046" num="0046"><u>Cell line and maintenance :</u> A PER.C6<sup>®</sup> cell line was used in this study that produces a human IgG. Cells were maintained in a serum free commercial medium (EX-CELL™ VPRO medium, JRH Biosciences), supplemented with 6 mM L-glutamine (Gibco). The PER.C6<sup>®</sup> cell line is a human embryonic cell-line immortalised with adenovirus type-5 (ad5) E1 gene using a phosphoglyceratekinase promoter.</p><p id="p0047" num="0047"><u>Bioreactor Set-up:</u> 1 L and 4L working volume reactors (Applikon, Netherlands and<!-- EPO <DP n="12"> --> B.Braun, Germany) were used during this study. A Braun DCU3 controller (B. Braun, Germany) was used to operate the process at defined setpoints. Temperature was maintained at 36.5°C (range 35.5-37.5 °C). Dissolved oxygen concentration was controlled at 50% (range 40-60%) of air saturation by automatic adjustment of inlet gas composition through the headspace and intermittent sparging through a microporous sparger. The pH setpoint was 7.1 (range 6.7-7.5) and controlled by the flow of CO<sub>2</sub> via the headspace. Cells were inoculated in the fermenter with an inoculum viable cell density range of 0.2-0.5 *10<sup>6</sup> cells/mL. Perfusion started at a viable cell density in the range of 1-3*10<sup>6</sup> cells/mL.</p><p id="p0048" num="0048"><u>Cell Retention:</u> Cells were retained in the reactor using three different devices. First a spin filter with a 10µm pore size (GKD, Düren Germany) was used. Secondly, a Biosep ADI1015 cell retention system and controller (AppliSens, the Netherlands) was used. Finally an ATF-4 control unit and housing with associate hollow fiber membrane module (Refine Technology, USA) was assessed. The hollow fiber filter used was model CFP-2-E-8SIP (0.2 micron, Area: 4600cm<sup>2</sup>, Amersham Bioscience obtained from Magellan instruments, USA). To maintain a constant culture volume a level sensor control loop was in operation.</p><p id="p0049" num="0049"><u>Analytical methods:</u> A cell count from the bioreactor was performed using the trypan blue exclusion method. The number of viable cells was determined as follows: An amount of cells stained with trypan blue was transferred to a Fuchs Rosenthal haemacytometer. The chamber of the haemacytometer was placed under a microscope and an appropriate number of boxes was counted. The viable cell density was calculated using the following formula: <maths id="math0002" num="(2)"><math display="block"><mi>Viable cell density</mi><mspace width="1em"/><mfenced separators=""><msup><mrow><mi mathvariant="normal">X</mi><mo>⁢</mo><mn mathvariant="normal">10</mn></mrow><mn mathvariant="normal">5</mn></msup><mspace width="1em"/><mi>cells</mi><mo>/</mo><mi>ml</mi></mfenced><mo>=</mo><mfenced separators=""><mi mathvariant="normal">A</mi><mo>+</mo><mi mathvariant="normal">B</mi></mfenced><mspace width="1em"/><mi>x E</mi><mo>/</mo><mn mathvariant="normal">320</mn></math><img id="ib0002" file="imgb0002.tif" wi="121" he="13" img-content="math" img-format="tif"/></maths><br/>
Wherein
<ul><li>A = number of non-stained cells in square A</li><li>B = number of non-stained cells in square B</li><li>E = dilution factor</li></ul></p><p id="p0050" num="0050">Antibody concentration was determined by a analytical protein A column using a HPLC<!-- EPO <DP n="13"> --> with UV280nm absorption detection; the actual concentration was determined on basis of a calibration curve of a IgG1 reference standard.<!-- EPO <DP n="14"> --></p><heading id="h0004"><u>Results</u></heading><heading id="h0005"><u>Perfusion Cultures</u></heading><p id="p0051" num="0051">Results obtained with the above materials and methods are shown in <figref idrefs="f0001 f0002 f0003 f0004 f0005 f0006">Figures 1-6</figref>.</p><heading id="h0006"><u>Legends to the Figures:</u></heading><p id="p0052" num="0052"><ul><li><figref idrefs="f0001">Figure 1</figref>: Viable cell density (x10<sup>6</sup> cells/ml) versus culture time (days) for two different continuous perfusion fermentations of an IgG1 producing PER.C6<sup>®</sup> clone using a spinfilter separation device. Stirrer speed setting of the 1 L Applikon fermenter was 100-150rpm. The perfusion runs were performed in 1 L working volume. The specific perfusion rate (SPR) for both perfusion runs was 0.1-0.3 nL/cell/day. In both cases the perfusion runs had to be terminated because of spin filter clogging.</li><li><figref idrefs="f0002">Figure 2</figref>: Growth of IgG1 producing PER.C6<sup>®</sup> cells in a continuous perfusion system with an acoustic device as a cell retention system. Stirrer speed setting of the 1 L Applikon fermenter was 100-150rpm. The settings used for the run/stop cycle were 300s forward and 4.5s backwards. During the run this was adapted to a 300s/3s cycle (day 15). The specific perfusion rate (SPR) for the perfusion run was between 0.1-0.3 nL/cell/day.</li><li><figref idrefs="f0003">Figure 3</figref>: Growth of IgG1 producing PER.C6<sup>®</sup> cells in a continuous perfusion system with an ATF-4 unit as a cell retention system. The experiment was performed in a 4L Applikon fermenter. Setting for the stirrer speed was 125 rpm. The ATF-4 operated between 0.5 and 3 working volumes per day. The SPR was set at 0.03-0.08 nL/cell/day. The inset shows the high cell density of the culture, being completely devoid of aggregating cells.</li><li><figref idrefs="f0004">Figure 4</figref>: Productivity of IgG1 versus culture time (days) for two different continuous perfusion fermentations of a IgG1 producing PER.C6<sup>®</sup> clone using a spin filter separation device.</li><li><figref idrefs="f0005">Figure 5</figref>: Productivity of IgG1 producing PER.C6™ cells in a continuous perfusion system with an acoustic device as a cell retention system.</li><li><figref idrefs="f0006">Figure 6</figref>: Productivity of IgG1 producing PER.C6<sup>®</sup> cells in a continuous perfusion system with an ATF unit as a cell retention system.</li></ul><!-- EPO <DP n="15"> --></p><heading id="h0007"><u>Summary</u></heading><p id="p0053" num="0053">See Table 1 for an overview of the data obtained for the different types of perfusion.
<tables id="tabl0001" num="0001"><table frame="all"><title>Table 1. Overview of the viable cell density, volumetric production rate (based on reactor volume) and the yield improvement of the perfusion runs using the three different retention devices. Batch and fed-batch results are added for comparison (data not shown).</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="42mm"/><colspec colnum="2" colname="col2" colwidth="42mm"/><colspec colnum="3" colname="col3" colwidth="42mm"/><colspec colnum="4" colname="col4" colwidth="41mm"/><thead><row><entry valign="top">Process</entry><entry valign="top">Max. Viable Cell Density (10<sup>6</sup> cells/mL)</entry><entry valign="top">Productivity</entry><entry valign="top">Yield (total amount of product produced) Improvement Factor</entry></row></thead><tbody><row><entry>Batch</entry><entry>8-10</entry><entry>0.5 g/L</entry><entry>1</entry></row><row><entry>Fed-Batch</entry><entry>8-10</entry><entry>1.2 g/L</entry><entry>2.4</entry></row></tbody></tgroup><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="42mm"/><colspec colnum="2" colname="col2" colwidth="42mm"/><colspec colnum="3" colname="col3" colwidth="42mm"/><colspec colnum="4" colname="col4" colwidth="41mm"/><thead><row><entry namest="col1" nameend="col4" align="left" valign="top">Continuous Perfusion</entry></row></thead><tbody><row><entry>Spin filter retention device</entry><entry>20-30</entry><entry>0.1-0.2 g/L/day</entry><entry>2.8-5.6</entry></row><row><entry>Acoustic retention device</entry><entry>20</entry><entry>0.6 g/L/day</entry><entry>16.8</entry></row><row><entry>ATF retention device</entry><entry>100</entry><entry>0.9 g/L/day</entry><entry>25.2</entry></row></tbody></tgroup></table></tables></p><p id="p0054" num="0054">It can be concluded that continuous perfusion experiments using the ATF unit show significant potential to achieve very high cell densities and product concentrations (100x10<sup>6</sup> cells/mL and 0.9 g/Uday), while no aggregation of the PER.C6® cells was observed.</p><heading id="h0008"><b><u>Example 2: Culturing of PER.C6® cells by perfusion.</u></b></heading><p id="p0055" num="0055"><u>Equipment</u>: B.Braun fermenter control unit (Braun, Germany), 7L Braun vessel and headplate with associated pH, dissolved oxygen (DO) and level sensor probes (Braun, Germany), ATF-4 control unit and housing with associate hollow fiber membrane module (Refine Technology, USA).</p><heading id="h0009"><u>Filter</u></heading><p id="p0056" num="0056"><ul><li>Filter model: CFP-2-E-8SIP</li><li>Type: 0.2 micron</li><li>Area: 4600 cm<sup>2</sup></li><li>Amersham Bioscience</li></ul><!-- EPO <DP n="16"> --></p><heading id="h0010"><u>Working volume</u></heading><p id="p0057" num="0057"><ul><li>Setpoint: 4.1 L</li><li>Range: 3.8 - 4.7 L</li></ul></p><heading id="h0011"><u>ATF settings</u></heading><p id="p0058" num="0058"><tables id="tabl0002" num="0002"><table frame="all"><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="44mm"/><colspec colnum="2" colname="col2" colwidth="16mm"/><colspec colnum="3" colname="col3" colwidth="16mm"/><thead><row><entry valign="top">Parameter</entry><entry valign="top">Setpoint</entry><entry valign="top">Range</entry></row></thead><tbody><row><entry>Pressure rising setpoint (psi)</entry><entry>Variable</entry><entry>2 - 4</entry></row><row><entry>Pressure rising flow (L/min)</entry><entry>3.2</entry><entry>2.5 - 4.0</entry></row><row><entry>Exhaust flow (L/min)</entry><entry>3.2</entry><entry>2.5 - 4.0</entry></row><row><entry>Exhaust time (s)</entry><entry>Variable</entry><entry>3 - 8</entry></row><row><entry>Pre-pressure (psi)</entry><entry>Variable</entry><entry>5 - 9</entry></row></tbody></tgroup></table></tables></p><heading id="h0012"><u>Bleed rate</u></heading><p id="p0059" num="0059">No biomass removal was applied to this process.</p><p id="p0060" num="0060"><u>Materials:</u> 6 mM (final volume) L-glutamine (Gibco) in Ex-CELL™ VPRO medium (JRH Bioscience, USA), 12% Na<sub>2</sub>CO<sub>3</sub> is used to control the pH.</p><heading id="h0013"><u>Cell Lines and Culture Conditions</u></heading><p id="p0061" num="0061">A PER.C6® cell line expressing a model IgG was investigated in this study. The PER.C6® cell line is generated from retina-derived primary human cells. The PER.C6® cell line is able to generate complete human monoclonal antibodies (including the glycans) (ref 1, ref 2).<br/>
Cells were cultured in shaking Erlenymer flasks at 110 rpm and 36.5°C. The headspace of these flasks was controlled using a mixture of 5% CO<sub>2</sub>/Air.
<ul><li>Ref 1: <nplcit id="ncit0006" npl-type="s"><text>Jones, D. H., van Berkel, P. H. C., Logtenberg, T. and Bout, A., 2002, 'PER.C6 cell line for human antibody production', Gen. Eng. News 22, 50-54</text></nplcit>.</li><li>Ref 2: <nplcit id="ncit0007" npl-type="s"><text>Jones, D. et al., 2003, 'High-level expression of recombinant IgG in the human cell line PER.C6', Biotechnol. Prog. 19, 163-168</text></nplcit>.</li></ul></p><heading id="h0014"><u>Operation of Fermenter</u></heading><p id="p0062" num="0062">Cells were cultured in a fermenter where dissolved oxygen tension, pH, temperature and agitation rate were controlled as detailed below.<!-- EPO <DP n="17"> -->
<tables id="tabl0003" num="0003"><table frame="all"><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="18mm"/><colspec colnum="3" colname="col3" colwidth="40mm"/><colspec colnum="4" colname="col4" colwidth="41mm"/><thead><row><entry valign="top">Parameter</entry><entry valign="top">Setpoint</entry><entry namest="col3" nameend="col4" align="left" valign="top">Range</entry></row></thead><tbody><row><entry>Temperature</entry><entry>36.5°C</entry><entry namest="col3" nameend="col4" align="left">35.5 - 37.5</entry></row><row><entry>pH</entry><entry>&gt; 6.7</entry><entry namest="col3" nameend="col4" align="left">7.5 - 6.7</entry></row><row><entry/><entry/><entry namest="col3" nameend="col4" align="left">Active pH control using 12% Na<sub>2</sub>CO<sub>3</sub> if pH&lt;6.7</entry></row><row><entry>DO</entry><entry>50%</entry><entry namest="col3" nameend="col4" align="left">40 - 60%</entry></row><row><entry morerows="8">Agitation</entry><entry morerows="8">100 - 300</entry><entry namest="col3" nameend="col4" align="left">Staged increase as viable cell density (VCD) increases;</entry></row><row><entry>VCD (x10<sup>6</sup> cells/ml)</entry><entry>Agitation (rpm)</entry></row><row><entry>0.3 - 10</entry><entry>120</entry></row><row><entry>10 - 30</entry><entry>150</entry></row><row><entry>30 - 50</entry><entry>170</entry></row><row><entry>50 - 80</entry><entry>200</entry></row><row><entry>80 - 100</entry><entry>230</entry></row><row><entry>100 - 120</entry><entry>260</entry></row><row><entry>&gt;120</entry><entry>300</entry></row></tbody></tgroup></table></tables></p><heading id="h0015"><u>Process Description:</u></heading><p id="p0063" num="0063">Cells are inoculated in a fermenter with an inoculation viable cell density range of 0.2 - 0.5 x 10<sup>6</sup> cells/ml and a setpoint of 0.3 x 10<sup>6</sup> cells/ml. Perfusion is begun when the viable cell density &gt; 2 x 10<sup>6</sup> cells /ml or at day 5 of the culture whichever is achieved first.<br/>
The perfusion rate is dependent on the cell density of the culture and the rates used are described in the table below. Both the flow rate and the dilution rate are adjusted as the cell density in the fermenter increases.</p><heading id="h0016"><u>Perfusion rates utilized for culture of PER.C6® cells</u></heading><p id="p0064" num="0064"><tables id="tabl0004" num="0004"><table frame="all"><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="50mm"/><colspec colnum="2" colname="col2" colwidth="53mm"/><colspec colnum="3" colname="col3" colwidth="64mm"/><thead><row><entry valign="top">Viable cell density (x10<sup>6</sup> cells/ml)</entry><entry valign="top">Specific perfusion rate (nl/cell/day)</entry><entry valign="top">Setpoint of specific perfusion rate (nl/cell/day)</entry></row></thead><tbody><row><entry>Day 1 of perfusion</entry><entry>0.15 - 0.25</entry><entry align="char" char=".">0.2</entry></row><row><entry>3 - 50</entry><entry>0.03 - 0.06</entry><entry align="char" char=".">0.04</entry></row><row><entry>50 -80</entry><entry>0.025 - 0.035</entry><entry align="char" char=".">0.03</entry></row><row><entry>&gt;80</entry><entry>0.01 - 0.03</entry><entry align="char" char=".">0.02</entry></row></tbody></tgroup></table></tables></p><p id="p0065" num="0065">The actual data and results from this example (amongst others flow rates and specific perfusion rates used in this example) are shown in Table 2 below and in <figref idrefs="f0007">Figures 7</figref> and <figref idrefs="f0008">8</figref>.</p><p id="p0066" num="0066"><figref idrefs="f0007">Figure 7</figref>: Culture time (days) versus flow (L/day) and specific perfusion rate (SPR in nl/cell/day) for PER.C6® cells cultured using a perfusion process.<br/>
<figref idrefs="f0008">Figure 8</figref>: Viable cell density and cell viability using the procedure described in example 2.<!-- EPO <DP n="18"> -->
<tables id="tabl0005" num="0005"><table frame="all"><title><u>Table 2. Raw data obtained for example 2</u></title><tgroup cols="9"><colspec colnum="1" colname="col1" colwidth="13mm"/><colspec colnum="2" colname="col2" colwidth="14mm"/><colspec colnum="3" colname="col3" colwidth="22mm"/><colspec colnum="4" colname="col4" colwidth="19mm"/><colspec colnum="5" colname="col5" colwidth="16mm"/><colspec colnum="6" colname="col6" colwidth="17mm"/><colspec colnum="7" colname="col7" colwidth="25mm"/><colspec colnum="8" colname="col8" colwidth="21mm"/><colspec colnum="9" colname="col9" colwidth="21mm"/><thead><row><entry align="center" valign="middle">Time</entry><entry align="center" valign="middle">flow rate (FR)</entry><entry align="center" valign="middle">dilution rate (D)</entry><entry align="center" valign="middle">Specific perfusion rate (SPR)</entry><entry align="center" valign="middle">Viable count (VC)</entry><entry align="center" valign="middle">Viability</entry><entry align="center" valign="middle">product concentration</entry><entry align="center" valign="middle">Specific production rate of IgG1</entry><entry align="center" valign="middle">Volumetric production rate</entry></row><row><entry align="center" valign="middle">day</entry><entry align="center" valign="middle">L/day</entry><entry align="center" valign="middle">working volume/day</entry><entry align="center" valign="middle">nL/cell.day</entry><entry align="center" valign="middle">10<sup>6</sup>/mL</entry><entry align="center" valign="middle">%</entry><entry align="center" valign="middle">g/L</entry><entry align="center" valign="middle">pg/(cell .day)</entry><entry align="center" valign="middle">g/L.day</entry></row></thead><tbody><row><entry align="center">0</entry><entry align="center">0.00</entry><entry align="char" char=".">0.00</entry><entry align="char" char=".">0.00</entry><entry align="center">0.6</entry><entry align="center">90</entry><entry align="char" char=".">0.012</entry><entry align="center">NA</entry><entry align="center">NA</entry></row><row><entry align="center">1</entry><entry align="center">0.00</entry><entry align="char" char=".">0.00</entry><entry align="char" char=".">0.00</entry><entry align="center">0.3</entry><entry align="center">77</entry><entry align="char" char=".">0.008</entry><entry align="center">NA</entry><entry align="center">0.000</entry></row><row><entry align="center">2</entry><entry align="center">0.00</entry><entry align="char" char=".">0.00</entry><entry align="char" char=".">0.00</entry><entry align="center">0.3</entry><entry align="center">73</entry><entry align="char" char=".">0.008</entry><entry align="center">0.0</entry><entry align="center">0.000</entry></row><row><entry align="center">3</entry><entry align="center">0.00</entry><entry align="char" char=".">0.00</entry><entry align="char" char=".">0.00</entry><entry align="center">0.5</entry><entry align="center">80</entry><entry align="char" char=".">0.013</entry><entry align="center">12.1</entry><entry align="center">0.000</entry></row><row><entry align="center">4</entry><entry align="center">0.00</entry><entry align="char" char=".">0.00</entry><entry align="char" char=".">0.00</entry><entry align="center">0.9</entry><entry align="center">87</entry><entry align="char" char=".">0.019</entry><entry align="center">9.3</entry><entry align="center">0.000</entry></row><row><entry align="center">5</entry><entry align="center">0.00</entry><entry align="char" char=".">0.00</entry><entry align="char" char=".">0.00</entry><entry align="center">1.4</entry><entry align="center">92</entry><entry align="char" char=".">0.033</entry><entry align="center">12.0</entry><entry align="center">0.000</entry></row><row><entry align="center">6</entry><entry align="center">2.39</entry><entry align="char" char=".">0.52</entry><entry align="char" char=".">0.20</entry><entry align="center">2.6</entry><entry align="center">95</entry><entry align="char" char=".">0.035</entry><entry align="center">5.5</entry><entry align="center">0.009</entry></row><row><entry align="center">7</entry><entry align="center">1.06</entry><entry align="char" char=".">0.24</entry><entry align="char" char=".">0.05</entry><entry align="center">4.9</entry><entry align="center">95</entry><entry align="char" char=".">0.054</entry><entry align="center">9.5</entry><entry align="center">0.017</entry></row><row><entry align="center">8</entry><entry align="center">2.70</entry><entry align="char" char=".">0.57</entry><entry align="char" char=".">0.08</entry><entry align="center">7.3</entry><entry align="center">97</entry><entry align="char" char=".">0.073</entry><entry align="center">7.2</entry><entry align="center">0.026</entry></row><row><entry align="center">9</entry><entry align="center">2.60</entry><entry align="char" char=".">0.57</entry><entry align="char" char=".">0.05</entry><entry align="center">12.3</entry><entry align="center">97</entry><entry align="char" char=".">0.067</entry><entry align="center">3.5</entry><entry align="center">0.040</entry></row><row><entry align="center">10</entry><entry align="center">4.29</entry><entry align="char" char=".">0.95</entry><entry align="char" char=".">0.05</entry><entry align="center">18.6</entry><entry align="center">97</entry><entry align="char" char=".">0.115</entry><entry align="center">7.8</entry><entry align="center">0.069</entry></row><row><entry align="center">11</entry><entry align="center">5.40</entry><entry align="char" char=".">1.20</entry><entry align="char" char=".">0.04</entry><entry align="center">26.9</entry><entry align="center">97</entry><entry align="char" char=".">0.140</entry><entry align="center">7.0</entry><entry align="center">0.137</entry></row><row><entry align="center">12</entry><entry align="center">6.80</entry><entry align="char" char=".">1.48</entry><entry align="char" char=".">0.05</entry><entry align="center">31.8</entry><entry align="center">96</entry><entry align="char" char=".">0.127</entry><entry align="center">5.6</entry><entry align="center">0.179</entry></row><row><entry align="center">13</entry><entry align="center">7.39</entry><entry align="char" char=".">1.68</entry><entry align="char" char=".">0.04</entry><entry align="center">41.4</entry><entry align="center">99</entry><entry align="char" char=".">0.129</entry><entry align="center">5.6</entry><entry align="center">0.202</entry></row><row><entry align="center">14</entry><entry align="center">8.28</entry><entry align="char" char=".">1.88</entry><entry align="char" char=".">0.04</entry><entry align="center">44.3</entry><entry align="center">98</entry><entry align="char" char=".">0.139</entry><entry align="center">5.8</entry><entry align="center">0.238</entry></row><row><entry align="center">15</entry><entry align="center">10.26</entry><entry align="char" char=".">2.33</entry><entry align="char" char=".">0.03</entry><entry align="center">68.3</entry><entry align="center">98</entry><entry align="char" char=".">0.116</entry><entry align="center">4.4</entry><entry align="center">0.269</entry></row><row><entry align="center">16</entry><entry align="center">10.70</entry><entry align="char" char=".">2.43</entry><entry align="char" char=".">0.03</entry><entry align="center">86.1</entry><entry align="center">99</entry><entry align="char" char=".">0.151</entry><entry align="center">4.6</entry><entry align="center">0.318</entry></row><row><entry align="center">17</entry><entry align="center">12.10</entry><entry align="char" char=".">2.63</entry><entry align="char" char=".">0.03</entry><entry align="center">80.3</entry><entry align="center">98</entry><entry align="char" char=".">0.163</entry><entry align="center">4.9</entry><entry align="center">0.397</entry></row><row><entry align="center">18</entry><entry align="center">11.83</entry><entry align="char" char=".">2.57</entry><entry align="char" char=".">0.02</entry><entry align="center">112.3</entry><entry align="center">98</entry><entry align="char" char=".">0.292</entry><entry align="center">7.6</entry><entry align="center">0.592</entry></row><row><entry align="center">19</entry><entry align="center">12.50</entry><entry align="char" char=".">2.78</entry><entry align="char" char=".">0.02</entry><entry align="center">123.0</entry><entry align="center">99</entry><entry align="char" char=".">0.291</entry><entry align="center">6.6</entry><entry align="center">0.780</entry></row><row><entry align="center">20</entry><entry align="center">12.09</entry><entry align="char" char=".">2.57</entry><entry align="char" char=".">0.02</entry><entry align="center">126.0</entry><entry align="center">99</entry><entry align="char" char=".">0.293</entry><entry align="center">6.3</entry><entry align="center">0.781</entry></row><row><entry align="center">21</entry><entry align="center">11.91</entry><entry align="char" char=".">2.59</entry><entry align="char" char=".">0.02</entry><entry align="center">135.0</entry><entry align="center">98</entry><entry align="char" char=".">0.332</entry><entry align="center">6.5</entry><entry align="center">0.806</entry></row><row><entry align="center">22</entry><entry align="center">13.70</entry><entry align="char" char=".">2.98</entry><entry align="char" char=".">0.02</entry><entry align="center">127.5</entry><entry align="center">97</entry><entry align="char" char=".">0.395</entry><entry align="center">8.2</entry><entry align="center">1.012</entry></row><row><entry align="center">23</entry><entry align="center">10.00</entry><entry align="char" char=".">2.17</entry><entry align="char" char=".">0.02</entry><entry align="center">128.5</entry><entry align="center">95</entry><entry align="char" char=".">0.470</entry><entry align="center">9.3</entry><entry align="center">1.114</entry></row></tbody></tgroup></table></tables></p></description><claims mxw-id="PCLM56987180" lang="DE" load-source="patent-office"><!-- EPO <DP n="20"> --><claim id="c-de-01-0001" num="0001"><claim-text>Verwendung eines Zellkultivierungsperfusions-verfahrens, wobei eine Zellkulturmedium und eine Suspension von Zellen umfassende Zellkultur im Kreislauf über ein Hohlfasern umfassendes Filter-modul geführt wird, wobei es sich bei dem Fluss über das Filtermodul um einen alternierenden Tangentialfluss handelt, zur Verringerung der Aggregation der Zellen in der Zellkultur, wobei diese Zellen dazu neigen, leicht oder von Natur aus Aggregate während der Kultivierung zu bilden, wobei nicht mehr als 5% der Zellen in der Kultur Aggregate in Suspension von wenigstens 5 Zellen bilden.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verwendung nach Anspruch 1, wobei es sich bei den aggregierenden Zellen um Säugerzellen handelt.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verwendung nach Anspruch 2, wobei es sich bei den Säugerzellen um CHO-Zellen, Hybridome, BHK-Zellen, Myelomzellen, menschliche Zellen oder Mäusezellen handelt.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Verwendung nach einem der Ansprüche 1-4, wobei Biomasse wenigstens einmal aus der Zellkultur entfernt und zusätzliches Zellkulturmedium zu der Zellkultur gegeben wird.</claim-text></claim></claims><claims mxw-id="PCLM56987181" lang="EN" load-source="patent-office"><!-- EPO <DP n="19"> --><claim id="c-en-01-0001" num="0001"><claim-text>Use of a perfusion cell culturing process wherein a cell culture comprising cell culture medium and a suspension of cells is circulated over a filter module comprising hollow fibers wherein the flow over the filter module is an alternating tangential flow, for the reduction of aggregation of the cells in the cell culture wherein these cells have the tendency to easily or inherently form aggregates during culturing wherein no more than 5% of the cells in the culture form aggregates in suspension of at least 5 cells.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>Use according to claim 1, wherein the aggregating cells are mammalian cells.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>Use according to claim 2, wherein the mammalian cells are CHO cells, hybridomas, BHK cells, myeloma cells, human cells or mouse cells.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>Use according to any of the claims 1 - 4, wherein biomass is removed at least once from the cell culture and additional cell culture medium is added to the cell culture.</claim-text></claim></claims><claims mxw-id="PCLM56987182" lang="FR" load-source="patent-office"><!-- EPO <DP n="21"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Utilisation d'un procédé de culture de cellules en perfusion, dans laquelle on fait circuler une culture cellulaire comprenant un milieu de culture de cellules et une suspension de cellules sur un module de filtration comprenant des fibres creuses, le flux sur le module de filtration étant un flux alternatif tangentiel, pour la réduction d'agrégation des cellules dans la culture cellulaire, ces cellules ayant la tendance de former facilement ou de façon inhérente des agrégats pendant la culture, où pas plus de 5 % des cellules en culture forment des agrégats en suspension d'au moins 5 cellules.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Utilisation selon la revendication 1, dans laquelle les cellules agrégantes sont des cellules de mammifère.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Utilisation selon la revendication 2, dans laquelle les cellules de mammifère sont des cellules CHO, des hybridomes, des cellules BHK, des cellules de myélome, des cellules humaines ou des cellules de souris.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Utilisation selon l'une quelconque des revendications 1 à 4, dans laquelle la biomasse est enlevée au moins une fois de la culture<!-- EPO <DP n="22"> --> cellulaire et on ajoute à la culture cellulaire du milieu de culture de cellules supplémentaire.</claim-text></claim></claims><drawings mxw-id="PDW16672674" load-source="patent-office"><!-- EPO <DP n="23"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="160" he="118" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="24"> --><figure id="f0002" num="2"><img id="if0002" file="imgf0002.tif" wi="159" he="112" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="25"> --><figure id="f0003" num="3"><img id="if0003" file="imgf0003.tif" wi="160" he="132" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="26"> --><figure id="f0004" num="4"><img id="if0004" file="imgf0004.tif" wi="144" he="115" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="27"> --><figure id="f0005" num="5"><img id="if0005" file="imgf0005.tif" wi="164" he="122" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="28"> --><figure id="f0006" num="6"><img id="if0006" file="imgf0006.tif" wi="153" he="132" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="29"> --><figure id="f0007" num="7"><img id="if0007" file="imgf0007.tif" wi="165" he="116" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="30"> --><figure id="f0008" num="8"><img id="if0008" file="imgf0008.tif" wi="162" he="137" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
